In this issue:
First-line atezolizumab/vemurafenib/cobimetinib for unresectable BRAF V600+ve melanoma
Anti-PD1 checkpoint inhibitors for acral melanoma
Nivolumab vs. everolimus in advanced renal cell carcinoma
Predicting outcomes and immune-related adverse events in PD1 inhibitor-treated advanced NSCLC
Outcomes associated with immune-related adverse events in nivolumab-treated metastatic NSCLC
Toxicities, body composition and QOL after anti-PD1/PD-L1 therapy
Sarcomatoid renal cell carcinoma: redefining first-line treatment
Neoadjuvant nivolumab for resectable Merkel cell carcinoma
Combined PD-L1 and CTLA-4 inhibition for CRC
Immune checkpoint inhibitor rechallenge after immunerelated adverse events
Please login below to download this issue (PDF)